查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715678

微生物組治療市場按產品、治療領域、配方、來源、最終用途和分銷管道分類－2025-2030 年全球預測

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

微生物組治療市場預計 2023 年將達到 9.8802 億美元，2024 年將達到 11.1894 億美元，複合年成長率為 14.45%，到 2030 年將達到 25.4245 億美元。

主要市場統計數據
基準年2023年 9.8802億美元
預計2024年 1,118,940,000美元
預測年份 2030 2,542,450,000美元
複合年成長率（%） 14.45%

微生物組療法是醫療保健領域的變革前沿，透過操縱微生物生態系統為長期存在的醫療挑戰提供創新解決方案。近年來，科學的突破開啟了旨在恢復人體平衡的標靶治療的新時代。這種方法不僅為透過新機制治療慢性和急性疾病鋪平了道路，而且挑戰了藥物開發的傳統範式。該領域的進步是由尖端研究、不斷增加的投資以及越來越多的檢驗微生物干預潛力的臨床證據共同推動的。隨著研究的進展和微生物組的複雜性變得更加清晰，決策者和相關人員有獨特的機會將這些新治療方法整合到標準治療方法中。本介紹概述說明探討了市場動態、策略性細分以及區域發展對微生物組療法未來的影響。

改變微生物組治療市場

微生物組治療領域正在經歷變革時期，重新定義醫療保健創新的輪廓。分子生物學和基因組學的進步揭示了微生物群落對人類健康的作用，從而帶來了新的治療方法和手段的出現。法律規範也在不斷發展，以跟上快速的技術創新，使研究成果能夠更快地轉化為臨床實踐。此外，加強學術界、生技公司和監管機構之間的跨部門合作對於促進創新和確保新治療方法符合安全性和有效性標準至關重要。數位化和數據分析也在改變臨床試驗的設計和實施方式方面發揮關鍵作用，使患者細分和治療個人化成為可能。這種轉變不僅突破了傳統藥物開發的界限，而且還帶來了強調靈活性和以患者為中心的新型經營模式。隨著相關人員重新考慮其投資重點和研究策略，人們感受到了微生物組療法重塑全球醫療保健服務的潛力。

微生物組治療市場動態的關鍵細分洞察

對市場區隔的詳細分析揭示了一個複雜且多方面的生態系統，這對於理解推動整體微生物組治療成長的因素至關重要。按產品檢驗市場，糞便微生物群移植、活生物治療、微生物組藥物、微生物組生態系統療法和益生菌/益生元等領域正受到關注，每個領域都有各自的優勢和挑戰。治療領域涵蓋廣泛的適應症，包括自體免疫疾病、癌症、胃腸病學、感染疾病、代謝疾病和神經系統疾病，確保創新能轉化為廣泛的臨床應用。此外，主要由口服和外用藥物組成的製劑部分反映了現代患者照護和治療依從性的動態要求。微生物組療法的來源也起著關鍵作用，動物、環境和人類微生物組之間的區別都導致了不同的治療途徑。按最終用途評估市場突出了學術和研究機構以及醫院和診所參與推動這些治療方法的臨床檢驗和實用化。最後，分銷管道分為線下藥局和線上藥局，線下部分進一步細分為醫院藥局和零售藥局，形成一個複雜的網路，確保廣泛的覆蓋率和強大的市場滲透力。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 文明病的盛行率不斷上升
      • 政府對微生物組研究和商業化的措施和資助
    • 限制因素
      • 微生物組治療產品召回的潛在風險
    • 機會
      • 利用微生物組療法促進女性荷爾蒙和生殖健康
      • 增加對人工智慧驅動的微生物組療法的投資
    • 任務
      • 與微生物組數據收集和治療用途相關的倫理和隱私問題
  • 市場區隔分析
    • 產品：針對慢性疾病的針對性介入對微生物組療法的需求不斷成長
    • 治療領域：自體免疫疾病對微生物組藥物的需求不斷增加，以減少發炎和調節免疫反應
    • 製劑：治療胃腸道疾病的口服製劑需求不斷成長
    • 資料來源：繼續研究利用動物微生物組了解腸腦軸和免疫調節
    • 最終用途：微生物組治療在學術創新中的演變
    • 交付管道：大力部署透過線上管道交付微生物組療法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 微生物組治療市場（依產品）

  • 糞便微生物移植
  • 活體生物治療公司
  • 微生物組醫學
  • 微生物生態系療法
  • 益生菌和益生元

7. 微生物組治療市場（依治療領域）

  • 自體免疫疾病
  • 癌症
  • 胃腸道疾病
  • 感染疾病
  • 代謝紊亂
  • 神經系統疾病

8. 微生物組治療市場（按劑型）

  • 口服
  • 話題

9. 微生物組治療市場（依來源）

  • 動物微生物組
  • 環境微生物組
  • 人類微生物組

第 10 章微生物組治療市場（依最終用途）

  • 學術研究所
  • 醫院和診所

第 11 章微生物組治療市場（依通路）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 網路藥局

12. 美國微生物醫學治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區微生物組治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲微生物組治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring BV
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.
Product Code: MRR-ED54C46E807C

The Microbiome Therapeutics Market was valued at USD 988.02 million in 2023 and is projected to grow to USD 1,118.94 million in 2024, with a CAGR of 14.45%, reaching USD 2,542.45 million by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 988.02 million
Estimated Year [2024] USD 1,118.94 million
Forecast Year [2030] USD 2,542.45 million
CAGR (%) 14.45%

Microbiome therapeutics represents a transformative frontier in healthcare where the manipulation of microbial ecosystems offers innovative solutions to longstanding medical challenges. In recent years, significant scientific breakthroughs have propelled the industry into a new era of targeted therapies aimed at restoring balance in the human body. This approach not only opens avenues for addressing chronic and acute diseases through novel mechanisms but also challenges traditional paradigms in drug development. The field's progression is underpinned by a combination of cutting-edge research, increasing investments, and a growing body of clinical evidence that validates the potential for microbial interventions. As research continues to unveil the complexities of microbiomes, decision-makers and stakeholders are presented with unique opportunities to integrate these emerging treatments into standard therapeutic regimens. This introductory overview sets the stage for an in-depth exploration of market dynamics, strategic segmentation, and the impact of regional developments that collectively shape the future of microbiome therapeutics.

Transformative Shifts in the Microbiome Therapeutics Landscape

The microbiome therapeutics landscape is undergoing transformative shifts that are redefining the contours of healthcare innovation. Advances in molecular biology and genomics have clarified the role of microbial communities in human health, leading to a surge of novel therapeutic approaches and treatment modalities. Regulatory frameworks are evolving to keep pace with rapid innovation, enabling faster translation of research insights into clinical practice. Furthermore, increased cross-sector collaboration between academia, biotechnology companies, and regulatory bodies is instrumental in fostering innovation and ensuring that emerging therapies meet both safety and efficacy standards. Digitalization and data analytics are also playing pivotal roles in transforming how clinical trials are designed and executed, allowing for more precise patient segmentation and treatment personalization. These shifts are not only pushing the boundaries of traditional drug development but are also inviting new business models that emphasize agility and patient-centric care. As stakeholders reconsider investment priorities and research strategies, there is a palpable momentum that underscores the potential for microbiome therapeutics to reshape global healthcare delivery.

Key Segmentation Insights on Market Dynamics in Microbiome Therapeutics

A detailed analysis of the market segmentation reveals a complex and multifaceted ecosystem that is critical to understanding the growth drivers across microbiome therapeutics. When examining the market based on products, considerable attention is given to areas such as Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics, each offering unique advantages and challenges. The therapeutic areas span a wide array of indications including Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders, ensuring that innovations have broad clinical applications. In addition, the formulation segment, comprising mainly oral and topical solutions, reflects the dynamic requirements of modern patient care and treatment compliance. The source of microbiome therapies also plays a pivotal role, with distinctions between Animal Microbiome, Environmental Microbiome, and Human Microbiome all contributing to diverse therapeutic pathways. Evaluating the market by end-use highlights the involvement of both Academic & Research Institutions and Hospitals & Clinics, which drive clinical validation and practical application of these therapies. Finally, the distribution channel is bifurcated into Offline and Online Pharmacies, with the offline segment further differentiated by Hospital Pharmacies and Retail Pharmacies, together creating an intricate network that ensures wide accessibility and robust market penetration.

Based on Products, market is studied across Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders.

Based on Formulation, market is studied across Oral and Topical.

Based on Source, market is studied across Animal Microbiome, Environmental Microbiome, and Human Microbiome.

Based on End-use, market is studied across Academic & Research Institutions and Hospitals & Clinics.

Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.

Key Regional Insights: Global Trends in Microbiome Therapeutics

The global landscape of microbiome therapeutics is marked by distinctive regional trends that underline both the maturity and growth potential of the industry. In the Americas, robust infrastructure and significant investments in biotechnology, combined with an active ecosystem of research collaboration, have positioned the region as a leader in both innovation and commercialization efforts. Meanwhile, the Europe, Middle East & Africa region displays a blend of established regulatory environments and emerging markets, creating a fertile ground for local and international partnerships. This diversity is evident in the way innovative practices are balanced with traditional healthcare systems to deliver patient-centric interventions. In the Asia-Pacific region, rapid economic growth and a surge in healthcare investments coupled with a high demand for advanced therapeutic solutions have spurred an increase in clinical research and adoption of microbiome-based treatments. Each of these regions presents unique market dynamics - from regulatory nuances to varied patient needs - that collectively drive global competitiveness and investment in microbiome therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Market Leaders Driving Innovation

A thorough exploration of the competitive landscape in microbiome therapeutics reveals a robust cadre of companies that are at the forefront of innovation. Key players include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., and BioGaia AB, among others. Companies such as BiomeBank, EnteroBiotix Ltd, Enterome SA, and Ferring B.V. have demonstrated a sustained commitment to developing therapies that leverage microbial dynamics to combat disease. In addition, innovators like Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., and MaaT Pharma SA are actively contributing to the diversification of product portfolios in the market. This ingenuity is further echoed by players such as Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, and Osel, Inc., as they navigate regulatory environments and continue to refine therapeutic formulations. Additionally, companies like Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, and Theriva Biologics, Inc. are forging new pathways in clinical development. The landscape is rounded out by Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd., whose strategic initiatives and commitment to research excellence underscore the competitive intensity and growth prospects within the sector.

The report delves into recent significant developments in the Microbiome Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., BioGaia AB, BiomeBank, EnteroBiotix Ltd, Enterome SA, Ferring B.V., Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., MaaT Pharma SA, Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, Osel, Inc., Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd.. Actionable Recommendations for Leading Industry Stakeholders

For industry stakeholders keen on harnessing the potential of microbiome therapeutics, several actionable recommendations can serve as a roadmap for sustained success and market leadership. First, it is crucial to invest in robust research and development programs that focus on the translational aspects of innovative microbiome therapies. Companies should streamline clinical trials and adopt adaptive study designs to accelerate regulatory approvals while mitigating risks related to therapeutic efficacy and safety. Second, fostering strategic partnerships across academic institutions, clinical research centers, and biotech innovators can create synergistic benefits that drive both discovery and market entry processes. Stakeholders should consider joint ventures and collaborative frameworks that facilitate the exchange of scientific insights, ultimately leading to a faster commercialization cycle. Third, aligning investment strategies with emerging patient needs, particularly in areas such as autoimmune diseases, cancer, and gastrointestinal disorders, will help companies tailor their products to a rapidly evolving market. In addition, leveraging digital health tools and data analytics can enhance market segmentation strategies by providing deeper insights into patient demographics and treatment responses. Finally, a proactive approach to navigating the regulatory landscape, with a strong focus on compliance and quality assurance, remains critical in ensuring that innovations are not only groundbreaking but also widely accessible and safe for public use.

Concluding Perspectives on the Future of Microbiome Therapeutics

In conclusion, the field of microbiome therapeutics stands at the intersection of unprecedented scientific discovery and the urgent need for innovative healthcare solutions. The collective insights derived from comprehensive market segmentation, regional trends, and competitive analysis underscore the immense potential of microbial therapies in reshaping the future of medicine. With robust advancements in research and development, coupled with an adaptive regulatory framework, stakeholders have a unique opportunity to address unmet clinical needs and pioneer new therapeutic paradigms. The ongoing evolution of product modalities, from fecal microbiota transplantation and live-biotherapeutics to microbiome drugs and ecosystem therapies, is testament to the depth and diversity within the market. Meanwhile, the convergence of academic research, clinical practice, and strategic investment sets the stage for continued growth and innovation. As the industry moves forward, a balanced approach that emphasizes collaboration, digital integration, and patient-centricity will be critical in unlocking the full potential of microbiome therapeutics and ensuring that these advancements translate into tangible societal benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of lifestyle-associated diseases
      • 5.1.1.2. Government initiatives and funding for microbiome research and commercialization
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recalls in microbiome therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging microbiome therapeutics for hormonal and reproductive health of women
      • 5.1.3.2. Growing investment in AI-driven microbiome-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and privacy concerns linked with microbiome data collection and usage in treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Products: Rising need of microbiome therapeutics for targeted interventions in chronic diseases
    • 5.2.2. Therapeutic Area: Growing demand of microbiome therapeutics in autoimmune diseases for reducing inflammation and modulating immune responses
    • 5.2.3. Formulation: Growing demand for oral formulations to address gastrointestinal conditions
    • 5.2.4. Source: Ongoing research for the use of animal microbiomes in understanding the gut-brain axis and immune modulation
    • 5.2.5. End-use: The evolving landscape of microbiome therapeutics for academic innovations
    • 5.2.6. Distribution Channel: Thriving microbiome therapeutics distribution through online channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Therapeutics Market, by Products

  • 6.1. Introduction
  • 6.2. Fecal Microbiota Transplantation
  • 6.3. Live-Biotherapeutics
  • 6.4. Microbiome Drugs
  • 6.5. Microbiome Ecosystem Therapies
  • 6.6. Probiotics & Prebiotics

7. Microbiome Therapeutics Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Gastrointestinal Disorders
  • 7.5. Infectious Diseases
  • 7.6. Metabolic Disorders
  • 7.7. Neurological Disorders

8. Microbiome Therapeutics Market, by Formulation

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Microbiome Therapeutics Market, by Source

  • 9.1. Introduction
  • 9.2. Animal Microbiome
  • 9.3. Environmental Microbiome
  • 9.4. Human Microbiome

10. Microbiome Therapeutics Market, by End-use

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Hospitals & Clinics

11. Microbiome Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Microbiome Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Microbiome Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Microbiome Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Kester Capital fuels growth for EMAS pharma in expanding CRO market
    • 15.3.2. AstraZeneca's USD 3.5 billion investment boosts microbiome therapeutics innovation in United States
    • 15.3.3. Biohm and ADM launch vivifem for targeted microbiome support in aging women
    • 15.3.4. Zymo Research and BluMaiden unite for advanced microbiome clinical analytics
    • 15.3.5. Nexilico and Siolta Therapeutics forge collaboration to advance treatments for infant NEC
    • 15.3.6. Metagen Therapeutics partners with JSR Corporation to establish an FMT drug manufacturing facility in Japan
    • 15.3.7. Seed Health expands retail presence with launch of probiotics in target stores nationwide
    • 15.3.8. Pendulum Therapeutics and BiomeSense unveiled microbiome research with continuous monitoring of Akkermansia muciniphila
    • 15.3.9. Kanvas Biosciences raised USD 12.5 million to progress microbiome-based immuno-oncology therapies
    • 15.3.10. Biolog, Inc. unveiled PreBioM microplates to advance gut microbiome characterization
    • 15.3.11. Nature Awards and Seed Health unite to launch microbiome accelerator solutions
    • 15.3.12. Seres Therapeutics enhanced the VOWST and achieved FDA Fast Track for SER-155
    • 15.3.13. Ferring B.V. signs partnership with PharmaBiome for development of microbiome-based therapies for gastrointestinal conditions
    • 15.3.14. Persephone Biosciences and Ginkgo Bioworks collaborate to enhance Bacteroides engineering for therapeutics development
    • 15.3.15. Microbiome Therapeutics Innovation Group expanded by joint venture with MaaT Pharma
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Enterome SA
    • 15.4.2. Xbiome Co. Ltd.
    • 15.4.3. Ferring B.V.
    • 15.4.4. Seres Therapeutics, Inc.

Companies Mentioned

  • 1. Alveolus Bio, Inc. by ResBiotic
  • 2. AOBiome LLC
  • 3. Assembly Biosciences, Inc.
  • 4. Axial Therapeutics, Inc.
  • 5. BioGaia AB
  • 6. BiomeBank
  • 7. EnteroBiotix Ltd
  • 8. Enterome SA
  • 9. Ferring B.V.
  • 10. Intralytix, Inc.
  • 11. Kanvas Biosciences
  • 12. Locus Biosciences, Inc.
  • 13. MaaT Pharma SA
  • 14. Microba Life Sciences Limited
  • 15. Microbiotica Ltd.
  • 16. MRM Health NV
  • 17. NuBiyota
  • 18. Osel, Inc.
  • 19. Pendulum Therapeutics
  • 20. PharmaBiome AG
  • 21. Pylum Biosciences
  • 22. Seres Therapeutics, Inc.
  • 23. Servatus Limited
  • 24. Siolta Therapeutics
  • 25. Theriva Biologics, Inc.
  • 26. Vedanta Biosciences, Inc.
  • 27. Viome Life Sciences, Inc. by BlueDot LLC
  • 28. Xbiome Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. MICROBIOME THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. MICROBIOME THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. MICROBIOME THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. MICROBIOME THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY LIVE-BIOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME ECOSYSTEM THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ANIMAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ENVIRONMENTAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HUMAN MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 327. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023